As the pan-European STOXX Europe 600 Index remains largely stable amidst a backdrop of stalled geopolitical negotiations and fluctuating oil prices, investors are keenly observing the region's economic indicators, such as Germany's rising inflation and Spain's unemployment rates. In this environment, dividend stocks can offer a measure of stability and income potential, making them an attractive option for those looking to navigate uncertain market conditions while potentially benefiting from...

Mota-Engil (FRA:M09) reports a record net profit and EBITDA growth, despite facing turnover declines due to external project delays.

If you’re wondering what to do with Mota-Engil SGPS stock, you’re definitely not alone. With shares up an outstanding 131.0% over the past year and an incredible 425.1% gain over the last three years, investors are right to question if the growth story still has room to run. Just in the past week, the stock surged another 13.0%. Part of this can be traced back to a wave of positive market sentiment in the infrastructure and construction sectors, fueled by hefty contract wins across Southern...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.